PCI Expands Illinois Pharmaceutical Manufacturing Facility
The expansion will enhance the company’s specialty drug product capabilities.
PCI Pharma Services, a pharmaceutical and biopharmaceutical outsourcing solutions provider based in Philadelphia, PA, announced on Dec. 4, 2019 that it completed an expansion at its Rockford, IL, facility to expand its specialty drug product capabilities.
The newly expanded facility is the largest of the company’s eights locations and features four high-potent-compound-capable suites built to ISO 8 standards, high-efficiency particle air filtration technology, three new secondary packaging areas, and three new coolers and a new freezer for 20 °C to -8 °C cold-chain requirements, according to a company press release.
“As we continue to see advancements in cancer and hormonal therapies, and growth in the allergen market, there is a stronger need in the marketplace for high potent compound suites,” said Angella Sutthiwan, vice president and general manager, PCI Pharma Services, in the press release.
The expansion comes after PCI revealed its new Clinical Center of Excellence at the Rockford site in September 2019.
“Across the globe, we are making strategic decisions that enable us to continue to support our clients’ business and meet increased demands for our integrated services,” said Salim Haffar, CEO, PCI Pharma Services, in the press release. “Our latest investment in the Rockford site is further evidence of our dedication to stay out in front of our clients’ needs and offer them the best and most innovative solutions in the industry.”
Source: PCI
